QQ客服 官方微博 反馈留言

	Development of 17 beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy
	Ning, Xiaohui[1,2]; Yang, Yan[3,4]; Deng, Hong[1,2]; Zhang, Qihao[3,4]; Huang, Yadong[3,4]; Su, Zhijian[3,4]; Fu, Yongmei[5]; Xiang, Qi[3,4]; Zhang, Shu[1,2]
	2017
卷号	121页码:10
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4454729
专题	暨南大学
作者单位	1.[1]Guangdong Pharmaceut Univ, Inst Mat Med, Guangzhou, Guangdong, Peoples R China 2.[2]Guangdong Pharmaceut Univ, Guangdong Prov Key Lab New Pharmaceut Dosage Form, Guangzhou, Guangdong, Peoples R China 3.[3]Jinan Univ, Inst Biomed, Guangzhou 510632, Guangdong, Peoples R China 4.[4]Jinan Univ, Guangdong Prov Key Lab Bioengn Med, Guangzhou 510632, Guangdong, Peoples R China 5.[5]Sinophami Grp Guangdong Medi World Pharmaceut Co, Foshan 528200, Peoples R China
推荐引用方式 GB/T 7714	Ning, Xiaohui[1,2],Yang, Yan[3,4],Deng, Hong[1,2],et al. Development of 17 beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy[J],2017,121:10.
APA	Ning, Xiaohui[1,2].,Yang, Yan[3,4].,Deng, Hong[1,2].,Zhang, Qihao[3,4].,Huang, Yadong[3,4].,...&Zhang, Shu[1,2].(2017).Development of 17 beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.,121,10.
MLA	Ning, Xiaohui[1,2],et al."Development of 17 beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy".121(2017):10.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。